A new Phase 3 clinical trial involving lanreotide was registered as of September 25, 2026. The study, titled "Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms," is listed under identifier NCT07842172.
According to the registration, the trial's status is not yet recruiting. It is designed to compare somatostatin analogue treatment, including lanreotide, against observation alone following peptide receptor radionuclide therapy in patients with nonfunctional neuroendocrine neoplasms.
The trial is registered as Phase 3. No participant enrollment has begun, and no outcomes or results have been reported at this stage. As the study has not yet started recruiting, no efficacy or safety data are currently available.
Lanreotide remains an approved compound. This trial registration reflects only the planned design and current recruitment status of the study, not any findings.
Readers interested in additional background can consult the compound overview for further context on lanreotide.